

Research

Open Access

## MG-132, an inhibitor of proteasomes and calpains, induced inhibition of oocyte maturation and aneuploidy in mouse oocytes

John B Mailhes\*<sup>1</sup>, Colette Hilliard<sup>1</sup>, Mary Lowery<sup>2</sup> and Steve N London<sup>1</sup>

Address: <sup>1</sup>Department of Obstetrics and Gynecology Louisiana State University Health Sciences Center, P.O. Box 33932, Shreveport, Louisiana 71130 USA and <sup>2</sup>Department of Pathology, Louisiana State University Health Sciences Center, P.O. Box 33932, Shreveport, Louisiana 71130 USA

E-mail: John B Mailhes\* - [jmailh@lsuhsc.edu](mailto:jmailh@lsuhsc.edu); Colette Hilliard - [chilli@lsuhsc.edu](mailto:chilli@lsuhsc.edu); Mary Lowery - [mlower@lsuhsc.edu](mailto:mlower@lsuhsc.edu); Steve N London - [slondo@lsuhsc.edu](mailto:slondo@lsuhsc.edu)

\*Corresponding author

Published: 8 October 2002

Received: 19 August 2002

*Cell & Chromosome* 2002, 1:2

Accepted: 8 October 2002

This article is available from: <http://www.cellandchromosome.com/content/1/1/2>

© 2002 Mailhes et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

**Keywords:** oocyte, chromosome, proteasome, MG-132

### Abstract

**Background:** Although chromosome missegregation during oocyte maturation (OM) is a significant contributor to human morbidity and mortality, very little is known about the causes and mechanisms of aneuploidy. Several investigators have proposed that temporal perturbations during OM predispose oocytes to aberrant chromosome segregation. One approach for testing this proposal is to temporarily inhibit the activity of protein proteolysis during OM. We used the reversible proteasome inhibitor MG-132 to transiently perturb the temporal sequence of events during OM and subsequently analyzed mouse metaphase II (MII) for cytogenetic abnormalities. The transient inhibition of proteasome activity by MG-132 resulted in elevated levels of oocytes containing extra chromatids and chromosomes.

**Results:** The transient inhibition of proteasome-mediated proteolysis during OM by MG-132 resulted in dose-response delays during OM and elevated levels of aneuploid MII oocytes. Oocytes exposed in vitro to MG-132 exhibited greater delays during metaphase I (MI) as demonstrated by significantly ( $p < 0.01$ ) higher levels of MI arrested oocytes and lower frequencies of premature sister chromatid separation in MII oocytes. Furthermore, the proportions of MII oocytes containing single chromatids and extra chromosomes significantly ( $p < 0.01$ ) increased with MG-132 dosage.

**Conclusions:** These data suggest that the MG-132-induced transient delay of proteasomal activity during mouse OM in vitro predisposed oocytes to abnormal chromosome segregation. Although these findings support a relationship between disturbed proteasomal activity and chromosome segregation, considerable additional data are needed to further investigate the roles of proteasome-mediated proteolysis and other potential molecular mechanisms on chromosome segregation during OM.

### Background

Although numerous hypotheses have been proposed to describe the etiology of aneuploidy in human gametes,

the only steadfast association remains maternal age [1,2]. Besides this association, very little information is available about the numerous potential mechanisms that may

disrupt normal chromosome segregation in oocytes. Based on studies involving compounds that alter microtubular kinetics and induce both cell-cycle delay and aneuploidy, several groups have proposed that temporal perturbations during mammalian oocyte maturation (OM) predispose oocytes to aneuploidy [3–6]. In addition to faulty microtubule kinetics, perturbations during OM may also stem from abnormal function of centrosomes, kinetochores, spindle checkpoint proteins, the anaphase-promoting complex (APC), the securin-separin-cohesion complex proteins, and the proteasome [7].

OM encompasses the nuclear and cytoplasmic changes that occur during the transition from the dictyotene stage of meiosis I to metaphase II (MII). During this transition, tightly-regulated post-translational phosphorylation-dephosphorylation events and proteasome-mediated proteolytic reactions regulate the activation and inactivation of signal transduction pathways that control chromatin condensation, nuclear membrane dissolution, microtubule nucleation, and formation of a haploid oocyte [8–10]. Several kinases that exert major roles during OM include maturation promoting factor (MPF) [9,11], mitogen-activated protein kinases (MAPKs) [12,13], and the product of the *c-mos* protooncogene *Mos* kinase [14,15]. Also, during OM oocytes undergo two highly-regulated metaphase-anaphase transitions (MAT) in which homologous chromosomes are equally and randomly segregated to an oocyte and first polar body and a subsequent division in which equational division of sister chromatids results in a haploid oocyte and a second polar body. The MATs are predicated upon the coordinated activities of the spindle checkpoint [16,17], the anaphase-promoting complex (APC) or cyclosome [18,19], the proteasome [20,21], and the cohesion-complex proteins involved with chromosome cohesion and separation [22–24]. Alterations in the temporal sequence of these coordinated activities may potentially predispose cells to faulty chromosome segregation.

Abnormal chromosome segregation has been observed in mice lacking the *Mad2* checkpoint protein [25]. The spindle checkpoint utilizes sensory proteins that detect kinetochore-microtubule tension and occupancy and transiently block anaphase until all of the chromosomes are properly attached to microtubules [16,26,27]. Although the mammalian spindle checkpoint appears to differ between mitosis and meiosis, the two meiotic divisions, and male and female germ cells [28], anaphase subsequently follows stable kinetochore-microtubule attachments [17,29] in both vertebrate mitotic [30] and meiotic [31] cells.


The APC is a large protein complex that ubiquitinates mitotic cyclins and other regulatory proteins that are destined for timely proteolysis by proteasomes [10,20].

Proteasomes are multicatalytic 26S proteases consisting of a 20S central core catalytic subunit bordered by two 19S components [32,33] which hydrolyze C-terminal peptide bonds to acidic, basic, and hydrophobic amino-acid residues [20,34]. Proteasomes proteolyze securins which inhibit separase activity. Separase is needed for inactivating cohesions and enabling sister chromatid separation [35–37] in both fission yeast [38] and mammalian cells [39]. Although differences have been reported among species [40] and cell types [41], it appears that the majority of cohesion is removed from mammalian chromosomes during prophase and prometaphase; whereas, a lesser amount remains at kinetochores until anaphase onset. Proteasomes translocated to meiotic spindles of rat oocytes and MG-132 induced-inhibition of proteasomal activity resulted in partial segregation of chromosomes during meiosis I [42]. Moreover, defective proteasomal activity in fission yeast impaired chromosome segregation [38].

To test the hypothesis that transient inhibition of proteasomal activity during mouse meiosis I was associated with chromosome missegregation, mouse oocytes were exposed *in vitro* to the reversible proteasome inhibitor MG-132 and metaphase II (MII) oocytes were analyzed for structural and numerical chromosome aberrations. This transient arrest of proteasomal activity represents a perturbation during the normal temporal sequence of events during OM.

## Results

Transient exposure of mouse oocytes to MG-132 for 6 h followed by washout of the compound and an additional 17 h culture *in vitro* enabled exposure of cells during meiosis I and sufficient time for them to progress to metaphase II. Although the majority of MII oocytes were classified as normal (Fig. 1A), the data indicated that MG-132 induced a dose-response perturbation or delay in the rate of OM and an increase of single, unpaired chromatids and hyperploidy in MII oocytes (Table 1). The significant ( $P < 0.01$ ) increase in the proportion of MI oocytes (Fig. 1B) in the 10.0 mcg/ml group relative to the other groups and the significant ( $P < 0.01$ ) decrease of oocytes exhibiting premature centromere separation (PCS) (Fig. 1C) in the 10.0 mcg/ml group relative to the controls suggest that proteasomal inhibition retarded the rate of OM. An inverse relationship has been shown to exist between the proportions of arrested MI oocytes and MII oocytes exhibiting PCS [43]. The significant ( $P < 0.01$ ) dose responses of higher frequencies of MII oocytes with single chromatids (Figs. 1C,1E) and of hyperploidy (Figs. 1D,1E) suggest that the MG-132-induced transient inhibition of proteasomal and calpain activities during meiosis I predisposed oocytes to abnormal chromosome segregation.



**Figure 1**  
**Cytogenetic analysis of mouse oocytes following in vitro exposure to MG-132, chromosome configurations are shown. (A)** metaphase II oocyte, normal,  $n = 20$  dyads. **(B)** metaphase I oocyte, normal,  $N = 20$  tetrads. **(C)** metaphase II oocyte, hypoploid, premature centromere separation (incomplete),  $n = 19 \frac{1}{2}$  (10 dyads and 19 chromatids), arrow points to one of the 19 single, unpaired chromatids. **(D)** metaphase II oocyte, hyperploid,  $n = 22$  dyads. **(E)** metaphase II oocyte, hyperploid, single-unpaired chromatid,  $n = 20 \frac{1}{2}$  (20 dyads and one single, unpaired chromatid indicated by arrow). **(F)** metaphase I oocyte, diffuse chromatin,  $N = 20$  probable tetrads. **(G)** metaphase I oocyte, homologous separation,  $N = 20$  (17 tetrads and 6 dyads), arrow points to one of the 6 dyads. **(H)** metaphase I oocyte, homologous separation,  $N = 19 \frac{1}{2}$  (16 tetrads and 7 dyads).

When oocytes were continuously exposed to 0.0, 0.5, 5.0, 25.0 or 50.0  $\mu\text{g/ml}$  MG-132 from one h after initiating the culture until 17 h later, the proportions of MI arrested oocytes were 5.7% (5/87), 12.3% (14/114), 39.3% (44/112), 100% (98/98), and 100% (91/91), respectively. Of the MI oocytes in the 25.0 and 50.0  $\mu\text{g/ml}$  MG-132 groups, 68.2% (30/44) and 100% exhibited diffuse chromatin (Fig. 1F); whereas, those oocytes continuously exposed to 0.0, 0.5 or 5.0  $\mu\text{g/ml}$  MG-132 did not display diffuse chromatin. Additionally, the proportions of MI

oocytes displaying homologue separation (Figs. 1G,1H) in oocytes transiently exposed to MG-132 for 6 h were 0% (0/13), 0% (0/19), 11.5% (3/26), 15.1% (8/53), respectively for 0.0, 5.0, 7.5, and 10.0  $\mu\text{g/ml}$  MG-132. Oocytes with premature anaphase, polyploidy, or structural chromosome aberrations were not found.

## Discussion

Proteasome activity is required for germinal vesicle breakdown (GVBD) in starfish and toad oocytes [44,45] and for activating *Xenopus* oocytes [45,46]. Also, proteasomes are needed for regulating centrosome segregation [38,47], kinetochore structure [39], and sister chromatid cohesion and separation [48]. When rat oocytes were exposed to the proteasome inhibitor MG132, proteasomes translocated to the meiotic spindle, MPF activity was sustained, and oocytes were arrested in MI with partially segregated chromosomes [42].

Besides inhibiting proteasome activity, the peptide aldehyde proteasome inhibitors have been also reported to repress certain lysosomal cysteine proteases and calpains [49]. The finding that MG-132 can obstruct the casein degrading activity of the calcium-dependent protease calpain [50] appears relevant to oocyte maturation. Calpain activity is needed for proteolysis of the c-mos proto-oncogene product pp39 mos in *Xenopus* oocytes [51], certain cytoskeletal proteins (alpha-tubulin, actin, dynamin, lamin B) in starfish oocytes [52], and of cyclin in *Xenopus* egg extracts [53].

We report that exposure of mouse oocytes to 10.0 mcg/ml MG-132 during meiosis I led to significant ( $P < 0.01$ ) increases in the proportions of MI arrested oocytes and of MII oocytes with SC and hyperploidy. Coupled with these findings was a significant ( $P < 0.01$ ) decrease in the incidence of MII oocytes exhibiting PCS (Table 1). Chemical induction of MI arrest in mammalian oocytes and spermatocytes indicates cell cycle retardation which is often associated with aneuploidy [43,54]. Although 10.0 mcg/ml MG-132 increased the frequency of MI arrested oocytes, this cell-cycle retardation may not be entirely attributed to proteasome inhibition. MG-132 can also inhibit calpains [50] which are needed for cell cycle progression [52] and cyclin degradation [53]. Previous studies [5,55] have shown that an inverse relationship usually exists between the proportions of arrested MI oocytes and MII oocytes exhibiting PCS. Oocytes residing in MII for longer periods of time tend to display higher frequencies of PCS; whereas, those deferred in MI spend less time in MII prior to fixation. The significant ( $P < 0.01$ ) increase in the proportions of MII oocytes exhibiting PCS in controls relative to the 10.0  $\mu\text{g/ml}$  group reflects the greater length of time that control oocytes spent in MII prior to fixation. We suggest that the PCS detected in MII

**Table 1: Cytogenetic analysis of mouse metaphase II oocytes following in vitro exposure to the proteasome inhibitor MG-132**

MG-132 (mcg/ml)	No. cells analyzed	No. MI oocytes (%)	No. MII oocytes (%)	No. premature centromere separation (%)	No. single chromatids (%)	No. haploid (%)	No. hypoploid (%)	No. hyperploid (%)
Control	130	13 (10.0) <sup>a</sup>	117 (90.0)	43 (36.8) <sup>a</sup>	1 (0.9) <sup>a</sup>	101 (86.3)	16 (13.7)	-0 <sup>a</sup>
5.0	158	19 (12.0) <sup>a</sup>	139 (88.0)	38 (27.3)	3 (2.2) <sup>a,b</sup>	121 (87.1)	18 (12.9)	-0 <sup>a</sup>
7.5	191	26 (13.6) <sup>a</sup>	165 (86.4)	44 (26.7)	11 (6.7) <sup>b</sup>	142 (86.1)	18 (10.9)	5 (3.0) <sup>b</sup>
10.0	125	53 (42.4) <sup>b</sup>	72 (57.6)	13 (18.1) <sup>b</sup>	11 (15.3) <sup>c</sup>	62 (86.1)	3 (4.2)	7 (9.7) <sup>c</sup>

Different superscripts among proportions in the same column indicate significant ( $P < 0.01$ ) differences.

oocytes mainly resulted from in vitro aging. As such, the frequencies of PCS noted in Table 1 would represent independent events relative to the other cytogenetic abnormalities reported.

On the other hand, PCS during meiosis I can result in aneuploid MII oocytes. PCS of homologous chromosomes and sister chromatids prior to establishing proper kinetochore-spindle attachment during meiosis I increases the probabilities of both homologues going to the same pole and of equational division of sister chromatids during anaphase I. Upon normal fertilization, MII oocytes with an additional chromosome result in trisomic zygotes; whereas oocytes containing an extra chromatid would be expected to produce 50% trisomic zygotes due to random segregation during anaphase II. This situation also applies to oocytes missing chromosomes and chromatids. Experimental data support PCS as a prelude to aneuploidy. PCS of homologues during meiosis I and equational division of sister chromatids during anaphase I [56,57] and premature separation of chromatids during meiosis II [58,59] and mitosis [60,61] have been shown to increase the incidence of aneuploidy in subsequent divisions. The partially segregated chromosomes found in rat oocytes exposed to MG-132 may have represented homologous chromosomes and/or sister chromatids [42].

The origin of single, unpaired chromatids in MII oocytes has been proposed to result from premature separation of sister chromatids prior to anaphase I [56,57]. The possibility exists that both SC and aneuploidy may have originated from PCS of homologues and sister chromatids during the MAT of meiosis I. Upon removal of MG-132 from the culture media during meiosis I and the subsequent resumption of OM and proteasomal activity, faulty kinetochore-microtubule attachment accompanied by degradation of cohesion proteins could conceivably lead to PCS of homologues and sister chromatids. Following anaphase I, a probability exists that both homologues and sister chromatids could randomly assort to the same pole and result in SC and aneuploid MII oocytes.

Although the frequency of homologue separation increased with MG-132 dose, the sample size of 11 oocytes is much too low to comment about their possible origin or their influence on other abnormalities detected in MII oocytes. The possibility exists that the observed homologue separation may actually reflect anaphase onset. The finding of diffuse chromatin in MI oocytes continuously exposed to 25.0 and 50.0  $\mu\text{g/ml}$  MG-132 may be related to the sustained elevation of MPF activity noted in rat oocytes exposed to MG-132 [42] and the stabilization of polyubiquitinated proteins and enhanced deubiquitination of nucleosomal histones in chromatin following proteasomal inhibition [62].

## Conclusions

The findings of the present study indicate that transient in vitro exposure of mouse oocytes to MG-132 is associated with abnormal chromosome segregation. However, additional data are clearly needed to further investigate the roles of calpain proteolysis and proteasome-mediated proteolysis on chromosome segregation as well as the numerous other potential molecular mechanisms of aneuploidy.

## Methods

### Animals

Female, ICR (Harlan Sprague-Dawley, Indianapolis, IN) mice between 26–33 g (8–12 wks of age) were used in all experiments. They were housed under ambient temperature of 21–23°C, relative humidity of 50  $\pm$  5%, and a 12-h light/12-h dark photoperiod. Feed and water were provided *ad libitum*. This research was approved by the Louisiana State University Health Sciences Center Animal Resources Advisory Committee.

### Oocyte collection, culture and exposure to MG-132

For each replicate experiment, five similarly treated mice received an intraperitoneal injection of 7.5 IU pregnant mare serum gonadotrophin (Dr. A.F. Parlow, National Hormone & Peptide Program, Torrance, CA) to augment the number of maturing follicles. Forty-six h later, the mice were euthanized by CO<sub>2</sub> inhalation and their reproductive tracts placed into Waymouth culture medium

(Gibco, Grand Island, New York, No. 11220-035). The ovaries were isolated and cumulus-oocyte complexes (COC) were liberated from antral follicles. The COC were then transferred to a 35 × 15 mm culture dish (Falcon No. 1008; Becton Dickinson, Co., Lincoln Park, NJ) containing 3 ml of complete culture medium (Waymouth medium, 942.7 ml, [Gibco No. 11220-035]; fetal bovine serum, 50 ml, [Gibco No. 16000-036]; penicillin-streptomycin [10,000 U/ml each of penicillin G sodium and streptomycin sulphate, 5 ml, [Gibco No. 15140-122]; pyruvic acid, 2.3 ml [Gibco No. 11360-070]; and 1 µg/ml FSH [NHPP, lot AFP-7028D]) and incubated at 37°C in a 5% CO<sub>2</sub> gaseous atmosphere. A stock solution of 150 µg/ml MG-132 (Z-leu-leu-CHO; Calbiochem, La Jolla, CA; No. 474790) was prepared in Waymouth medium containing 7.5 µL per ml. dimethylsulfoxide (DMSO) as the solvent.

MG-132 is a peptide aldehyde that inhibits ubiquitin-mediated proteolysis by binding to and inactivating 20S and 26S proteasomes [49,62]. Although 1–10 µM MG-132 inhibited first polar body extrusion in rat oocytes, its activity is reversible [42]. We conducted preliminary experiments to obtain a MG-132 dose range that would transiently perturb or inhibit OM during meiosis I while enabling oocytes to complete OM following washing out of the compound. Data from oocytes cultured in either 0.0, 0.5, 5.0, 25.0, or 50.0 µg/ml MG-132 from one h after initiating the culture until 17 h later showed that the two higher doses completely blocked oocytes in MI. On the other hand, when oocytes were exposed to these same MG-132 doses from one h after initiating the culture until 6 h later when the chemical was washed out (4X) and cultured for an additional 17 h in media without MG-132, oocytes exposed to 25.0 and 50.0 µg/ml MG-132 were still arrested in MI. Thus, data from these preliminary experiments enabled the selection of a protocol in which oocytes were placed into complete culture media and incubated for 1 h prior to adding either 0 (solvent only), 5.0, 7.5, or 10.0 µg/ml MG-132. Six h later, the MG-132 was washed out of the media by rinsing the oocytes four times in complete media without MG-132 and then re-incubated for 17 h. Under this protocol, oocytes were exposed to MG-132 during meiosis I and the subsequent 17 h culture time provided sufficient time for the oocytes to overcome the MG-132-induced meiotic block and progress to MII. Control oocytes were cultured in 7.5 µl DMSO per ml complete media and processed in the same manner as those exposed to MG-132.

#### Cytogenetic analysis and statistical analysis of data

Oocytes were collected and processed according to a mass-harvest procedure [63] and chromosomes were C-banded [64] to distinguish between complete dyads (MII chromosomes) and disjoined dyads (single chromatids).

In each cell analyzed, the number of chromosomes and/or chromatids was counted at 1000 × magnification to provide data for calculating aneuploidy. The number of hypoploid ( $n = 10-19 \frac{1}{2}$ ), haploid ( $n = 20$ ), hyperploid ( $n = 20 \frac{1}{2}-29 \frac{1}{2}$ ), and polyploid ( $n = 30-40$ ) MII oocytes were recorded. An oocyte classified as  $20 \frac{1}{2}$  contains 20 dyads and one chromatid or one-half dyad. The frequencies of each ploidy class were divided by the total number of MII oocytes analyzed excluding polyploidy. The frequencies of MII oocytes displaying premature centromere separation (PCS), single chromatids (SC), premature anaphase (PA) were also calculated relative to the total number of MII oocytes analyzed. Since MI and polyploid oocytes are distinct categories and are disregarded when computing aneuploidy, their frequencies were calculated relative to the total number of oocytes analyzed.

The criteria for eliminating a cell from analysis included: inadequate C-banding for discriminating between intact dyads and those separated at the centromere, overlapped or clumped chromosomes, or excessive chromosome scatter that precluded an objective analysis of numerical or structural aberrations. The frequencies of hyperploid cells were used as a measure of aneuploidy because an unknown proportion of the hypoploid cells is influenced by technical artifact resulting from excessive chromosome scatter during slide preparation. Chi-Square analysis and the Fisher's Exact Test were used for data analyses.

#### Author's contributions

Each author contributed substantially to the various aspects required for the timely completion of this study. Their respective efforts are reflected by the order of authorship.

#### References

1. EB Hook: **Maternal age, paternal age, and human chromosome abnormality: nature, magnitude, etiology, and mechanisms of effects.** In: *Aneuploidy: Etiology and Mechanisms* (Edited by: Dellarco VL, Voytek PE, Hollaender A) New York, Plenum Press 1985, 117-132
2. Hassold T, Sherman S: **The origin of non-disjunction in humans.** In: *Chromosomes Today* (Edited by: Sumner A, Chandley AC) London, Chapman and Hall 1993, 11:313-322
3. Hansmann I, Pabst B: **Nondisjunction by failures in the molecular control of oocyte maturation.** *Ann Anat* 1992, **174**:485-490
4. Eichenlaub-Ritter U: **Studies on maternal age-related aneuploidy in mammalian oocytes and cell cycle control.** In: *Chromosomes Today* (Edited by: Sumner AT, Chandley AC) London, Chapman & Hall 1993, 11:323-336
5. Mailhes JB, Marchetti F: **The influence of postovulatory ageing on the retardation of mouse oocyte maturation and chromosome segregation induced by vinblastine.** *Mutagenesis* 1994, **9**:541-545
6. Plachot M: **The human oocyte. Genetic aspects.** *Ann. Genet* 1997, **40**:115-120
7. Nasymth K: **Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis.** *Annu Rev Genet* 2001, **35**:673-745
8. Bornslaeger EA, Mattei P, Schultz RM: **Involvement of cAMP-dependent protein kinase and protein phosphorylation in regulation of mouse oocyte maturation.** *Dev Biol* 1986, **114**:453-462

9. Dekel N: **Protein phosphorylation-dephosphorylation in the meiotic cell cycle of mammalian oocytes.** *Rev Reprod* 1996, **1**:82-88
10. Kotani S, Tanaka H, Yasuda H, Todokoro K: **Regulation of APC activity by phosphorylation and regulatory factors.** *J Cell Biol* 1999, **146**:791-800
11. Downs SM, Daniel SAJ, Bornslaeger EA, Hoppe PC, Eppig JJ: **Maintenance of meiotic arrest in mouse oocytes by purines: modulation of cAMP levels and cAMP phosphodiesterase activity.** *Gamete Res* 1989, **23**:323-334
12. Moos J, Visconti PW, Moore GD, Schultz RM, Kopf GS: **Potential role of mitogen-activated protein kinase (MAP) in pronuclear envelope assembly and disassembly following fertilization of mouse eggs.** *Biol Reprod* 1995, **53**:692-699
13. Murray AW: **MAP kinases in meiosis.** *Cell* 1998, **92**:157-159
14. Paules RS, Buccione R, Moschel RC, Vande Woude GF, Eppig JJ: **Mouse mos protooncogene product is present and functions during oogenesis.** *Proc Natl Acad Sci.* 1989, **86**:5395-5399
15. Hashimoto N: **Role of c-mos proto-oncogene product in the regulation of mouse oocyte maturation.** *Horm Res* 1996, **46**:1-14
16. Amon A: **The spindle checkpoint.** *Curr Opin Genet Develop* 1999, **9**:69-75
17. Howell BJ, Hoffman DB, Fang G, Murray AW, Salmon ED: **Visualization of Mad2 dynamics at kinetochores, along spindle fibers, and at spindle poles in living cells.** *J Cell Biol* 2000, **150**:1233-1250
18. Page AM, Hieter P: **The anaphase-promoting complex: new subunits and regulators.** *Annu Rev Biochem* 1999, **68**:583-609
19. Nasmyth K, Peters JM, Uhlmann F: **Splitting the chromosome: cutting the ties that bind sister chromatids.** *Science* 2000, **288**:1379-1385
20. Glickman MH, Ciechanover A: **The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.** *Physiol Rev* 2002, **82**:373-428
21. Jesenberger V, Jentsch S: **Deadly encounter: ubiquitin meets apoptosis.** *Nat Rev Mol Cell Biol* 2002, **3**:112-121
22. Hagting A, den Elzen N, Vodermaier HC, Waizenegger IC, Peters JM, Pines J: **Human securin proteolysis is controlled by the spindle checkpoint and reveals when the APC/C switches from activation by Cdc20 to Cdh1.** *J Cell Biol* 2002, **157**:1125-1137
23. Hauf S, Waizenegger IC, Peters JM: **Cohesin cleavage by separase required for anaphase and cytokinesis in human cells.** *Science* 2001, **293**:1320-1323
24. Stemmann O, Zou H, Gerber SA, Gygi SP, Kirschner MW: **Dual inhibition of sister chromatid separation at metaphase.** *Cell* 2001, **107**:715-726
25. Dobles M, Liberal V, Scott ML, Benerza R, Sorger PK: **Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2.** *Cell* 2000, **101**:635-645
26. Dorée M, Le Peuch C, Morin N: **Onset of chromosome segregation at the metaphase to anaphase transition of the cell cycle.** *Prog Cell Cycle Res* 1995, **1**:309-318
27. Skibbens RV, Hieter P: **Kinetochores and the checkpoint mechanism that monitors for defects in the chromosome segregation machinery.** *Annu Rev Genet* 1998, **32**:307-337
28. Kallio M, Eriksson JE, Gorbisky GJ: **Differences in spindle association of the mitotic checkpoint protein Mad2 in mammalian spermatogenesis and oogenesis.** *Dev Biol* 2000, **225**:112-123
29. Sudakin V, Chan GK, Yen TJ: **Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2.** *J Cell Biol* 2001, **154**:925-936
30. Abrieu A, Magnaghi-Jaulin L, Kahana JA, Peter M, Castro A, Vigneron S, Lorca T, Cleveland DW, Labbe J-C: **Mps1 is a kinetochore-associated kinase essential for the vertebrate mitotic checkpoint.** *Cell* 2001, **106**:83-93
31. Shah JV, Cleveland DW: **Waiting for anaphase: Mad2 and the spindle assembly checkpoint.** *Cell* 2000, **103**:997-1000
32. Coux O, Tanaka K, Goldberg AL: **Structure and functions of the 20S and 26S proteasomes.** *Annu Rev Biochem* 1996, **65**:801-847
33. Goldberg AL: **Functions of the proteasome: the lysis at the end of the tunnel.** *Science* 1995, **268**:522-523
34. Elliott PJ, Ross JS: **The proteasome: a new target for novel drug therapies.** *Am J Clin Pathol* 2001, **116**:637-646
35. Jallepalli PV, Waizenegger I, Bunz F, Langer S, Speicher MR, Peters JM, Kirschner MW, Vogelstein B, Lengauer C: **Securin is required for chromosomal stability in human cells.** *Cell* 2001, **105**:445-457
36. Uhlmann F: **Secured cutting: controlling separase at the metaphase to anaphase transition.** *EMBO reports* 2001, **2**:487-492
37. Uhlmann F, Lottspeich F, Nasmyth K: **Sister chromatid separation at anaphase onset is promoted by cleavage of the cohesion subunit Scc1p.** *Nature* 1999, **400**:37-42
38. Javerzat JP, McGurk G, Cranston G, Barreau C, Bernard P, Gordon C, Allshire R: **Defects in components of the proteasome enhance transcriptional silencing at fission yeast centromeres and impair chromosome segregation.** *Mol Cell Biol* 1999, **19**:5155-5165
39. Paweletz N, Wojcik C, Schroeter D, Finze EM: **Are proteasomes involved in the formation of the kinetochore?** *Chromosome Res* 1996, **4**:436-442
40. Darwiche N, Freeman LA, Strunnikov A: **Characterization of the components of the putative mammalian sister chromatid cohesion complex.** *Gene* 1999, **233**:39-47
41. Van Heemst D, Heyting C: **Sister chromatid cohesion and recombination in meiosis.** *Chromosoma* 2000, **109**:10-26
42. Josefsberg LBY, Galiani D, Dantes A, Amsterdam A, Dekel N: **The proteasome is involved in the first metaphase-to-anaphase transition of meiosis in rat oocytes.** *Biol Reprod* 2000, **62**:1270-1277
43. Mailhes JB, Marchetti F: **The relationship between chemically-induced meiotic delay and aneuploidy in mouse oocytes and zygotes.** In: *Chromosome Segregation and Aneuploidy* (Edited by: Vig BK) Berlin, NATO ASI Series, Springer-Verlag 1993, **H72**:283-296
44. Takahashi M, Tokumoto T, Ishikawa K: **DFP-sensitive multicatalytic protease complexes (proteasomes) involved in the control of oocyte maturation in the toad, Bufo japonicus.** *Mol Reprod Dev* 1994, **38**:310-317
45. Sawada M, Kyoizuka K, Morinaga C, Izumi K, Sawada H: **The proteasome is an essential mediator of the activation of pre-MPF during starfish oocyte maturation.** *Biochem Biophys Res Commun* 1997, **236**:40-43
46. Tokumoto T, Yamashita M, Tokumoto M, Katsu Y, Horiguchi R, Kajjura H, Nagahama Y: **Inhibition of cyclin B degradation by the 26S proteasome upon egg activation.** *J Cell Biol* 1997, **138**:1313-1322
47. Ochi T: **Role of mitotic motors, dynein and kinesin, in the induction of abnormal centrosome integrity and multipolar spindles in cultured V79 cells exposed to dimethylarsinic acid.** *Mutat Res* 2002, **499**:73-84
48. Zou H, McGarry TJ, Bernal T, Kirschner MW: **Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis.** *Science* 1999, **285**:418-422
49. Lee DH, Goldberg AL: **Proteasome inhibitors: valuable new tools for cell biologists.** *Trends Cell Bio* 1998, **8**:397-403
50. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S: **Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine.** *J Biochem* 1996, **119**:572-576
51. Watanabe N, Vande Woude G, Ikawa Y, Sagata N: **Specific proteolysis of the c-mos proto-oncogene product by calpain on fertilization of Xenopus eggs.** *Nature* 1989, **342**:505-511
52. Santella L, Kyoizuka K, Hoving S, Munchbach M, Quadroni M, Dainese P, Zamparelli C, James P, Carafoli E: **Breakdown of cytoskeletal proteins during meiosis of starfish oocytes and proteolysis induced by calpain.** *Exp Cell Res* 2000, **259**:117-126
53. Lorca T, Galas S, Fesquet D, Devault A, Cavadore JC, Dorée M: **Degradation of the proto-oncogene product p39mos is not necessary for cyclin proteolysis and exit from meiotic metaphase: requirement for a Ca(2+)-calmodulin dependent event.** *EMBO J* 1991, **10**:2087-2093
54. Adler I-D, Gassner P, Schriever-Schwemmer G, Min ZR: **Correlation between induction of meiotic delay and aneuploidy in male mouse germ cells.** In: *Chromosome Segregation and Aneuploidy* (Edited by: Vig B K) Berlin, NATO ASI Series, Springer-Verlag 1993, **H72**:297-308
55. Mailhes JB: **Important biological variables that can influence the degree of chemical-induced aneuploidy in mammalian oocyte and zygotes.** *Mutat Res* 1995, **339**:155-176
56. Angell RR: **Predivision in human oocytes a meiosis I: a mechanism for trisomy formation in man.** *Hum Genet* 1991, **86**:383-387
57. Soewarto D, Schimiady H, Eichenlaub-Ritter U: **Consequences of non-extrusion of the first polar body and control of the se-**

- quential segregation of homologues and chromatids in mammalian oocytes *Hum Reprod* 1995, **10**:2350-2360
58. Mailhes JB, Young D, London SN: **1,2-Propanediol-induced premature centromere separation in mouse oocytes and aneuploidy in one-cell zygotes.** *Biol Reprod* 1997, **57**:92-98
  59. Mailhes JB, Young D, London SN: **Postovulatory ageing of mouse oocytes in vivo and premature centromere separation and aneuploidy.** *Biol Reprod* 1998, **58**:1206-1210
  60. Fitzgerald PH, Pickering AF, Mercer JM, Miethke PM: **Premature centromere division: A mechanism of non-disjunction causing X chromosome aneuploidy in somatic cells of man.** *Ann Hum Genet* 1975, **38**:417-428
  61. Gabarron J, Jimenez A, Glover G: **Premature centromere division dominantly inherited in a subfertile family.** *Cytogenet Cell Genet* 1986, **43**:69-71
  62. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: **Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.** *Cell* 1994, **78**:767-771
  63. Mailhes JB, Yuan ZP: **Cytogenetic technique for mouse metaphase II oocytes.** *Gamete Res* 1987, **18**:77-83
  64. Salamanca F, Armendaras S: **C-bands in human metaphase chromosomes treated by barium hydroxide** *Ann Genet* 1974, **17**:135-136

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>



**BioMedcentral.com**

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)